Barclays
ABMD

Barclays’s Abiomed Inc ABMD Stock Holding History

Barclays’s Portfolio ABMD Stock Details ABMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-19,700
Closed -$2.86M – 6435
2020
Q1 		$2.86M Buy
19,700
+19,400
+6,467% +$3.22M ﹤0.01% 1953
2019
Q4 		$51K Sell
300
-300
-50% -$55.6K ﹤0.01% 5737
2019
Q3 		$107K Buy
600
+100
+20% +$21.6K ﹤0.01% 5433
2019
Q2 		$130K Sell
500
-9,900
-95% -$2.63M ﹤0.01% 5483
2019
Q1 		$2.97M Buy
10,400
+9,900
+1,980% +$3.29M ﹤0.01% 2152
2018
Q4 		$163K Sell
500
-1,700
-77% -$591K ﹤0.01% 4721
2018
Q3 		$989K Buy
2,200
+900
+69% +$355K ﹤0.01% 3627
2018
Q2 		$532K Sell
1,300
-300
-19% -$109K ﹤0.01% 3897
2018
Q1 		$466K Buy
+1,600
New +$405K ﹤0.01% 4051
2015
Q1 		– Sell
-100
Closed -$4K – 7318
2014
Q4 		$4K Hold
100
– – ﹤0.01% 7028
2014
Q3 		$2K Hold
100
– – ﹤0.01% 7435
2014
Q2 		$3K Hold
100
– – ﹤0.01% 7320
2014
Q1 		$3K Sell
100
-600
-86% -$16.6K ﹤0.01% 7351
2013
Q4 		$18K Sell
700
-3,400
-83% -$84K ﹤0.01% 6774
2013
Q3 		$78K Sell
4,100
-10,800
-72% -$247K ﹤0.01% 5812
2013
Q2 		$321K Buy
+14,900
New +$299K ﹤0.01% 4717

Other funds holding ABMD

TRSOTSOK
Teachers Retirement System of the State of Kentucky Frankfort, Kentucky $14.7B AUM 42.39% 1-Year Est. Return
BTI
Blue Trust Inc Alpharetta, Georgia $9.54B AUM 19.86% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $59.2B AUM 26.02% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $65.2B AUM 31.44% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
AW
Avion Wealth The Woodlands, Texas $537M AUM 18.24% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $20.6B AUM 34.61% 1-Year Est. Return

Barclays's ABMD Position: Q4 2022 in Review

Barclays sold out of Abiomed Inc (ABMD) in Q4 2022, closing a stake of 50,218 shares — an estimated $12.3M sold.

Barclays first reported a position in ABMD in Q2 2013 and held it in 38 quarters. The position peaked at $29.2M in Q3 2018. 8 funds tracked by Wall St. Rank hold ABMD as of Q4 2022.

  • Barclays reported no remaining Abiomed Inc position as of Q4 2022 after selling out during the quarter.
  • Barclays sold 50,218 Abiomed Inc shares in Q4 2022, an estimated $12.3M.
  • Barclays first reported a position in Abiomed Inc in Q2 2013 and held it in 38 quarters.
  • Barclays's Abiomed Inc position peaked at $29.2M in Q3 2018.
  • 8 funds tracked by Wall St. Rank held Abiomed Inc as of Q4 2022.

Based on Barclays's 13F filing for Q4 2022, filed 13 Feb 2023.